MCID: SPN051
MIFTS: 53

Spondylitis

Categories: Bone diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Spondylitis

MalaCards integrated aliases for Spondylitis:

Name: Spondylitis 11 75 53 43 14 71

Classifications:



External Ids:

Disease Ontology 11 DOID:6590
ICD9CM 34 720.8
MeSH 43 D013166
SNOMED-CT 68 202651004
ICD10 31 M46
UMLS 71 C0029644 C0038012

Summaries for Spondylitis

MalaCards based summary: Spondylitis is related to juvenile ankylosing spondylitis and ankylosing spondylitis 1, and has symptoms including sciatica An important gene associated with Spondylitis is HLA-B (Major Histocompatibility Complex, Class I, B), and among its related pathways/superpathways are MIF Mediated Glucocorticoid Regulation and Akt Signaling. The drugs Loxoprofen and Aceclofenac have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and t cells, and related phenotypes are Increased shRNA abundance (Z-score > 2) and immune system

Wikipedia: 75 Spondylitis is an inflammation of the vertebrae. It is a form of spondylopathy. In many cases,... more...

Related Diseases for Spondylitis

Diseases related to Spondylitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1455)
# Related Disease Score Top Affiliating Genes
1 juvenile ankylosing spondylitis 32.7 TNF ERAP1
2 ankylosing spondylitis 1 32.6 IL17A HLA-B CRP
3 fibromyalgia 32.1 TNF IL6 IL1B CRP
4 spondyloarthropathy 1 32.0 TNF TAP2 NOD2 IL6 IL23R IL1B
5 back pain 31.6 IL6 IL1B CRP
6 synovitis 31.2 TNF IL6 IL1B CRP
7 spondylarthropathy 31.1 TNF LTA CRP
8 bowel dysfunction 31.1 TNF NOD2 IL6 IL1B CRP
9 osteoarthritis 31.1 TNF IL6 IL1B IL17A CRP
10 osteomyelitis 31.0 TNF NOD2 IL6 IL1B CRP
11 uveitis 31.0 TNF NOD2 LTA IL6 IL23R IL1B
12 spondylosis 30.9 TNF IL6 IL1B CRP
13 glomerulonephritis 30.9 TNF IL6 IL1B CRP
14 radiculopathy 30.8 IL6 IL17A CRP
15 aortic aneurysm 30.8 TNF IL6 IL1B CRP
16 ankylosis 30.8 TNF SOST IL17A ERAP1 CRP CCR6
17 atherosclerosis susceptibility 30.8 TNF IL6 IL1B CRP
18 pulmonary tuberculosis 30.8 TNF IL6 IL1B CRP
19 arachnoiditis 30.8 TNF IL1B CRP
20 gout 30.8 TNF IL6 IL1B HLA-B CRP
21 reactive arthritis 30.8 TNF TAP2 IL17A HLA-B ERAP1 CRP
22 bursitis 30.7 TNF IL6 IL1B CRP
23 endocarditis 30.7 TNF IL6 IL17A CRP
24 psoriasis 1 30.7 MICA IL23R IL17A HLA-C CCR6
25 cartilage disease 30.7 TNF IL6 IL1B CRP
26 leptin deficiency or dysfunction 30.7 TNF IL6 IL1B CRP
27 conjunctivitis 30.6 TNF IL6 HLA-B
28 neuritis 30.6 TNF IL6 IL1B
29 amyloidosis 30.6 TNF SAA1 IL6 IL1B CRP
30 vasculitis 30.6 TNF IL6 IL1B IL17A HLA-B CRP
31 relapsing polychondritis 30.6 TNF IL6 CRP
32 psoriatic arthritis 30.5 TNF NOD2 MICA LTA IL6 IL23R
33 periodontitis 30.5 TNF IL6 IL1B IL17A CRP
34 paine syndrome 30.5 TNF IL6 IL1B
35 chlamydia 30.5 TNF IL6 IL1B IL17A CRP
36 brucellosis 30.5 TNF SAA1 IL6 IL17A HLA-B CRP
37 apnea, obstructive sleep 30.5 TNF IL6 IL1B CRP
38 anterior uveitis 30.5 TNF IL6 IL23R IL1B IL17A HLA-B
39 bronchiectasis 30.5 TNF IL6 IL1B CRP
40 takayasu arteritis 30.5 TNF IL6 IL23R HLA-B CRP
41 myositis 30.4 TNF IL6 IL1B IL17A HLA-B
42 serum amyloid a amyloidosis 30.4 TNF SAA1 IL6 CRP
43 nephrotic syndrome 30.4 TNF IL6 IL1B IL17A CRP
44 juvenile rheumatoid arthritis 30.4 TNF LTA IL6 IL1B CRP CCR6
45 adult syndrome 30.4 TNF IL6 CRP
46 macular retinal edema 30.4 TNF IL6 IL1B
47 prostatitis 30.4 TNF IL6 IL1B IL17A
48 pericardial effusion 30.4 TNF IL6 CRP
49 proteasome-associated autoinflammatory syndrome 1 30.4 TNF IL6 IL1B IL17A CRP
50 sleep apnea 30.4 TNF IL6 IL1B CRP

Comorbidity relations with Spondylitis via Phenotypic Disease Network (PDN):


Acute Cystitis

Graphical network of the top 20 diseases related to Spondylitis:



Diseases related to Spondylitis

Symptoms & Phenotypes for Spondylitis

UMLS symptoms related to Spondylitis:


sciatica

GenomeRNAi Phenotypes related to Spondylitis according to GeneCards Suite gene sharing:

25 (show all 17)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 10.18 CCR6 CRP ERAP1 ERAP2 HLA-B HLA-C
2 no effect GR00402-S-2 10.18 CCR6 CRP ERAP1 ERAP2 HLA-B HLA-C
3 Increased shRNA abundance (Z-score > 2) GR00366-A-11 9.89 MICA
4 Increased shRNA abundance (Z-score > 2) GR00366-A-118 9.89 HLA-B HLA-C
5 Increased shRNA abundance (Z-score > 2) GR00366-A-121 9.89 MICA
6 Increased shRNA abundance (Z-score > 2) GR00366-A-124 9.89 HLA-C
7 Increased shRNA abundance (Z-score > 2) GR00366-A-139 9.89 MICA
8 Increased shRNA abundance (Z-score > 2) GR00366-A-149 9.89 HLA-C
9 Increased shRNA abundance (Z-score > 2) GR00366-A-162 9.89 HLA-C
10 Increased shRNA abundance (Z-score > 2) GR00366-A-210 9.89 NOD2
11 Increased shRNA abundance (Z-score > 2) GR00366-A-36 9.89 NOD2
12 Increased shRNA abundance (Z-score > 2) GR00366-A-46 9.89 MICA
13 Increased shRNA abundance (Z-score > 2) GR00366-A-47 9.89 HLA-C
14 Increased shRNA abundance (Z-score > 2) GR00366-A-57 9.89 MICA
15 Increased shRNA abundance (Z-score > 2) GR00366-A-74 9.89 HLA-B HLA-C
16 Increased shRNA abundance (Z-score > 2) GR00366-A-83 9.89 MICA
17 Increased shRNA abundance (Z-score > 2) GR00366-A-93 9.89 HLA-C

MGI Mouse Phenotypes related to Spondylitis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 9.83 CCR6 CRP ERAP1 HLA-B HLA-C IL17A
2 no phenotypic analysis MP:0003012 9.8 ERAP1 HLA-B HLA-C IL17A IL23A IL23R
3 digestive/alimentary MP:0005381 9.76 HLA-B HLA-C IL17A IL23A IL23R IL6
4 hematopoietic system MP:0005397 9.47 CCR6 ERAP1 HLA-B HLA-C IL17A IL1B

Drugs & Therapeutics for Spondylitis

Drugs for Spondylitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 180)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Loxoprofen Approved Phase 4 80382-23-6, 68767-14-6 3965
2
Aceclofenac Approved, Investigational Phase 4 89796-99-6 71771
3
Hydroxychloroquine Approved Phase 4 118-42-3 3652
4
Etoricoxib Approved, Investigational Phase 4 202409-33-4 123619
5
Pamidronic acid Approved Phase 4 40391-99-9 4674
6
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
7
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
8
Golimumab Approved Phase 4 476181-74-5
9
Certolizumab pegol Approved Phase 4 428863-50-7
10
Abatacept Approved Phase 4 332348-12-6
11
Upadacitinib Approved, Investigational Phase 4 1310726-60-3 76829165 58557659
12
Ixekizumab Approved, Investigational Phase 4 1143503-69-8
13
Tofacitinib Approved, Investigational Phase 4 477600-75-2 9926791
14
Rebamipide Approved, Investigational Phase 4 90098-04-7 5042
15
Etanercept Approved, Investigational Phase 4 185243-69-0
16
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
17
Diclofenac Approved, Vet_approved Phase 4 15307-86-5, 15307-79-6 3033
18
Meloxicam Approved, Vet_approved Phase 4 71125-38-7 54677470 5281106
19
Acetaminophen Approved Phase 4 103-90-2 1983
20
Tramadol Approved, Investigational Phase 4 27203-92-5 33741 5523
21
Esomeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6, 119141-88-7 9568614 4594
22
Indomethacin Approved, Investigational Phase 4 53-86-1 3715
23
Ubidecarenone Approved, Investigational, Nutraceutical Phase 4 303-98-0 5281915
24 Natriuretic Peptide, Brain Phase 4
25 Anti-Infective Agents Phase 4
26 Endothelial Growth Factors Phase 4
27 Mitogens Phase 4
28 Pharmaceutical Solutions Phase 4
29 Cholestyramine Resin Phase 4
30 Antiprotozoal Agents Phase 4
31 Antiparasitic Agents Phase 4
32 Antimalarials Phase 4
33 Tripterygium Phase 4
34 Anesthetics Phase 4
35 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
36 Adrenergic alpha-Antagonists Phase 4
37 Anti-Arrhythmia Agents Phase 4
38 Sodium Channel Blockers Phase 4
39 Anesthetics, Local Phase 4
40
Triamcinolone hexacetonide Phase 4
41
Triamcinolone diacetate Phase 4
42
Triamcinolone Acetonide Phase 4 6436
43 Diuretics, Potassium Sparing Phase 4
44 Immune Checkpoint Inhibitors Phase 4
45 Tumor Necrosis Factor Inhibitors Phase 4
46 Janus Kinase Inhibitors Phase 4
47 Protein Kinase Inhibitors Phase 4
48 Anti-Bacterial Agents Phase 4
49 Angiogenesis Inhibitors Phase 4
50 Vaccines Phase 4

Interventional clinical trials:

(show top 50) (show all 597)
# Name Status NCT ID Phase Drugs
1 Efficacy and Safety of Etanercept Dose Reduction in Patients With Ankylosing Spondylitis Unknown status NCT02638896 Phase 4 etanercept (Half-Dose);etanercept (Full-Dose);Sulfasalazine;Celecoxib
2 Treat-to-target Strategy in Ankylosing Spondylitis Using Etanercept and Conventional Synthetic DMARDs, a Prospective Randomized Controlled Study Unknown status NCT04077957 Phase 4 Methotrexate;Sulfasalazine;Hydroxychloroquine;Etanercept (50mg per week, for 4 weeks);Etanercept (50mg per week, for 2 weeks);Etanercept (50mg per week)
3 The Efficacy of Adalimumab and Conventional Antirheumatic Drugs in Alleviating Axial and Aortic Inflammation Detected in PET/CT in Patients With Axial Spondyloarthritis Unknown status NCT02634541 Phase 4 Adalimumab
4 Effects of Biological Treatment on Blood Pressure and Endothelial Function in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Unknown status NCT02132234 Phase 4 Etanercept;Adalimumab;Certolizumab;Infliximab
5 Prospective Evaluation of Heart Function by Echocardiographic Study, Pro-brain Natriuretic Peptide Type B and Troponin T in Patients With Rheumatoid Arthritis and Ankylosing Spondylitis Pre and Post-TNF Blocker Unknown status NCT01072058 Phase 4 TNF blockers (infliximab, adalimumab, etanercept)
6 Combined Treatment With TNF (Tumor Necrosis Factor) Inhibitor and Pamidronate in AS Patients: Effect on the Radiographic Progression Unknown status NCT02313727 Phase 4 Pamidronate
7 Etanercept Versus Adalimumab in the Treatment of Patients With Ankylosing Spondylitis. A Switch Study Unknown status NCT02489760 Phase 4
8 TReat-to-tArget (T2T) With seCukinumab in Axial Spondyloarthritis. IdEntification of MRI and Biochemical Biomarkers for Disease Activity, Treatment Response and Structural Damage Progression (the TRACE Study) Unknown status NCT03639740 Phase 4 Secukinumab 150 milligram [Cosentyx]
9 A Multicenter,Double-Blind and Randomized Controlled Trial of Fengshigutong Capsule in the Treatment of Ankylosing Spondylitis Unknown status NCT03932006 Phase 4 Fengshigutong Capsule plus Imrecoxib;Fengshigutong Capsule;Imrecoxib
10 Can New Imaging- and Bio-markers Improve the Assessment of Disease Activity and Progression and Predict Therapeutic Outcome in Spondyloarthritis Patients Receiving Adalimumab Unknown status NCT00477893 Phase 4 Adalimumab;Placebo
11 Risk of Tuberculosis and Infections in Spondyloarthritis Patients Treated With Tofacitinib in Bangladesh Unknown status NCT03504072 Phase 4 Tofacitinib 5 mg,;Etanercept
12 Efficacy and Safety of Loxoprofen Hydrogel Patch Versus Loxoprofen Tablet in Patients With Ankylosing Spondylitis: a 4-week Randomized, Open-label Study Completed NCT03800797 Phase 4 Loxoprofen sodium hydrogel patch;Loxoprofen sodium tablet
13 Baseline Serum Vascular Endothelial Growth Factor (VEGF) Concentration as Predictive Factor of Response to Infliximab (Remicade) Therapy in Patients With Active Ankylosing Spondylitis Despite Conventional Treatment: a Multicenter Pilot Study Completed NCT00779935 Phase 4
14 Whole Human Genome Oligo Microarray Analysis of the Peripheral Blood Mononuclear Cells of Patients With Ankylosing Spondylitis During Infliximab Treatment Compared to Healthy Controls Completed NCT00778869 Phase 4
15 Effects of NSAIDs on RAdiographic Damage in Ankylosing Spondylitis (ENRADAS) - a Prospective Randomised Controlled Trial Completed NCT00715091 Phase 4 diclophenac
16 Effect of Methotrexate on the Relation Dose-effect of Infliximab in Ankylosing Spondylitis Completed NCT00507403 Phase 4 infliximab
17 Multicentre, Open-Labeled Study Of Etanercept In The Treatment Of Patients With Ankylosing Spondylitis Completed NCT00458185 Phase 4 etanercept
18 An Open-Label Multicentre Long-Term Extension Study of Etanercept in Ankylosing Spondylitis Completed NCT00444340 Phase 4 Enbrel (Etanercept)
19 Effect of the Combination of Methotrexate and Adalimumab on Reduction of Immunization in Ankylosing Spondylitis (COMARIS) Completed NCT01895764 Phase 4 Adalimumab;Methotrexate
20 A Phase-IV, Multicenter, Noncomparative, Open-Label Study Evaluating the Safety and Efficacy of Golimumab (a Fully Human Anti-TNFα Monoclonal Antibody, Administered Subcutaneously) in the Treatment of Indian Patients With Active Spondyloarthropathy of Ankylosing Spondylitis or Psoriatic Arthritis Completed NCT03733925 Phase 4 Golimumab
21 COmparison of the Effect of Treatment With NSAIDs Added to Anti-TNF Therapy Versus Anti-TNF Therapy Alone on Progression of StrUctural Damage in the Spine Over Two Years in Patients With ankyLosing Spondylitis: a Randomized Controlled Multicentre Trial Completed NCT02758782 Phase 4 Celecoxib
22 Post-Registration Open-Label, Non-Comparative, Multicenter Study of Rate of Efficacy and Tolerance of the Use of Anti-TNF Chimeric Monoclonal Antibodies (Remicade) in Treatment of Patients With Active Ankylosing Spondylitis Completed NCT00779012 Phase 4
23 The Efficacy of Combination Methotrexate and Infliximab in Patients With Ankylosing Spondylitis:A Clinical and Magnetic Resonance Imaging Correlation Completed NCT00432432 Phase 4 Infliximab and MTX
24 Chung Shan Medical University Hospital, Taiwan Completed NCT00647517 Phase 4 Ultracet
25 A Randomized, Double-blind, Parallel-group, Multicenter Study of Secukinumab to Compare 300 mg and 150 mg at Week 52 in Patients With Ankylosing Spondylitis Who Are Randomized to Dose Escalation After Not Achieving Inactive Disease During an Initial 16 Weeks of Open-label Treatment With Secukinumab 150 mg (ASLeap) Completed NCT03350815 Phase 4 150 mg open-label secukinumab;150 mg double-blinded secukinumab;300 mg double-blinded secukinumab
26 A Randomized, Double-blind, Placebo-controlled Multicenter Study of Secukinumab (AIN457) to Examine the Clinical Efficacy and the NSAID-sparing Effect of Secukinumab Over 16 Weeks in Patients With Ankylosing Spondylitis (ASTRUM) Completed NCT02763046 Phase 4 Secukinumab (AIN457) 150 mg s.c.;Placebo - Secukinumab (AIN457) 150 mg s.c.
27 A Multicentre, Double-Blind, Placebo-Controlled, Randomised Study of Etanercept in the Treatment of Adult Patients With Active, Severe, and Advanced Axial Ankylosing Spondylitis Completed NCT00420238 Phase 4 Etanercept (Enbrel)
28 An Open-label, Multicentre, Supplementary Extension Study of Etanercept in Subjects With Ankylosing Spondylitis Completed NCT00410046 Phase 4 Enbrel (etanercept)
29 A Multi-center, Open Label, Random Clinical Trial of Etanercept and Celecoxib Alone/Combined Treatment in Effectiveness and Safety of Active Ankylosing Spondylitis Completed NCT01934933 Phase 4 celebrex;Enbrel;Enbrel plus Celebrex
30 A 12-week Randomized, Double-blind, Multicenter Pilot Study to Evaluate the Effect of Etanercept 100 mg and 50 mg Weekly in Subjects With Ankylosing Spondylitis Completed NCT00873730 Phase 4 etanercept;etanercept/placebo
31 Biomarkers Identification of Anti-TNF α Agent's Efficacy in Ankylosing Spondylitis Patients Using a Transcriptome Analysis and Mass Spectrometry Completed NCT02492217 Phase 4 Adalimumab
32 A MULTICENTER OPEN-LABEL STUDY OF ETANERCEPT WITHDRAWAL AND RETREATMENT IN SUBJECTS WITH NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS WHO ACHIEVED ADEQUATE 24 WEEK RESPONSE Completed NCT02509026 Phase 4
33 TNFalfa Blocking Treatment of Spondylarthropathies - A Danish Multicenter Study of New Methods for Better Monitoring and Prognostifying Patients With Spondylarthropathies Completed NCT00133315 Phase 4 Infliximab;Etanercept;Adalimumab
34 A Clinical Trial About the Efficacy and Safety of Kunxian Capsule in Treatment Patients With Early Ankylosing Spondylitis: a 12-week, Multi-center, Randomized, Double-blind, Active Drug and Placebo Compared Clinical Trial Completed NCT00953979 Phase 4 kunxian capsule
35 A Randomized, Double-Blind Study Evaluating the Safety and Efficacy of Etanercept and Sulphasalazine in Subjects With Ankylosing Spondylitis Completed NCT00247962 Phase 4 etanercept;sulphasalazine (SSZ)
36 Open-Label, Phase 4 Study, Investigating the Incidence of Extra-Articular Manifestations in Subjects With Ankylosing Spondylitis Treated With Golimumab; Protocol No. MK-8259-012 Completed NCT01668004 Phase 4
37 An Open Trial to Evaluate the Efficacy and Safety of Infliximab(Remicade) in Treating Patients With Early Ankylosing Spondylitis Completed NCT00936143 Phase 4 infliximab
38 Sequential Application of Yisaipu® and Disease Modifying Anti-Rheumatic Drugs (DMARDs) in Treating Mild-to-Moderate Ankylosing Spondylitis: the Mid-term Follow-up Result Completed NCT03411798 Phase 4 Yisaipu®
39 A Twelve Week, Randomized, Double Blind Parallel Group Study Of Two Doses Of Celecoxib Compared To Diclofenac In Patients With Ankylosing Spondylitis Completed NCT02528201 Phase 4 Celecoxib 200 milligrams;Celecoxib 400 milligrams;diclofenac 50 milligrams
40 Effect of Anti-TNF(Alpha)Treatment on Circulating Endothelial Progenitor Cells (EPCs) and Vascular Stiffness in AS Completed NCT01212653 Phase 4 Simponi
41 Relapse of Ankylosing Spondylitis Patients Withdrawal Etanercept After Clinical Remission: a Three Years' Following-up Study Completed NCT02915354 Phase 4 Etanercept
42 Intestinal Inflammation in Ankylosing Spondylitis Assessed by Fecal Calprotectin, Capsular Endoscopy and Colonoscopy and the Effects of Adalimumab on Mucosal Healing Completed NCT01174186 Phase 4 Adalimumab
43 Total Glucosides Paeony Capsules in Maintaining Clinical Remission in Patients With Ankylosing Spondylitis Which Achieve Clinical Remission After Anti-TNF Therapy Completed NCT01517620 Phase 4 Total Glucosides Paeony Capsules
44 Multicenter, Open-Label Study to Assess the Effects of Certolizumab Pegol on the Reduction of Anterior Uveitis Flares in Axial Spondyloarthritis Subjects With a History of Anterior Uveitis (C-VIEW) Completed NCT03020992 Phase 4 Certolizumab Pegol
45 A Prospective Study of the Use of the Madrid Ultrasound Scoring System in the Treatment of Anti-TNF Blocker to Peripheral Tendonitis in Patients With Spondyloarthritis Completed NCT02960035 Phase 4 50mg etanercept;25mg etanercept;placebo
46 Combined Pneumococcal Conjugate and Polysaccharide Vaccination in Inflammatory Rheumatic Disease. Impact of Antirheumatic Treatment on Antibody Response. Completed NCT03762824 Phase 4
47 Ultrasound Guided Epidural Block in Axial SPA Patient With Limited Spine Mobility: a Prospective Pilot Randomized Controlled Trial Completed NCT04143165 Phase 4 Epidural block with lidocaine and triamcinilone
48 A RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP STUDY TO EVALUATE THE SAFETY AND EFFICACY OF SWITCHING FROM INNOVATOR INFLIXIMAB TO BIOSIMILAR INFLIXIMAB COMPARED WITH CONTINUED TREATMENT WITH INNOVATOR INFLIXIMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS, SPONDYLOARTHRITIS, PSORIATIC ARTHRITIS, ULCERATIVE COLITIS, CROHN'S DISEASE AND CHRONIC PLAQUE PSORIASIS THE NOR-SWITCH STUDY Completed NCT02148640 Phase 4 Innovator infliximab;Biosimilar infliximab
49 A Phase-IV, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Trial to Evaluate the Efficacy and Safety of Golimumab (MK-8259 [SCH 900259]) After Treatment Withdrawal, Compared With Continued Treatment (Either Full- or Reduced-Treatment Regimen), In Subjects With Non-Radiographic Axial Spondyloarthritis Completed NCT03253796 Phase 4
50 Treatment of Active Axial Spondyloarthritis by Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ IgG Fc Fusion Protein Injection: a Randomized, Double-blind, Multicentral Clinical Trial to Investigate the Efficacy and Safety of Yisaipu® Completed NCT02364479 Phase 4 50mg Yisaipu;25mg etanercept;Placebo

Search NIH Clinical Center for Spondylitis

Cochrane evidence based reviews: spondylitis

Genetic Tests for Spondylitis

Anatomical Context for Spondylitis

Organs/tissues related to Spondylitis:

MalaCards : Bone, Bone Marrow, T Cells, Endothelial, Placenta, Spinal Cord, Brain

Publications for Spondylitis

Articles related to Spondylitis:

(show top 50) (show all 18810)
# Title Authors PMID Year
1
Radiological sacroiliitis, a hallmark of spondylitis, is linked with CARD15 gene polymorphisms in patients with Crohn's disease. 53 62
15308523 2004
2
Animal models of inflammatory spinal and sacroiliac joint diseases. 53 62
12951872 2003
3
Effect of ozone therapy on neutrophil/lymphocyte, platelet/lymphocyte ratios, and disease activity in ankylosing spondylitis: a self-controlled randomized study. 62
36204783 2023
4
Spondylitis with epidural abscess and spinal tuberculoma as a major cause of myeloradiculopathy: a case report. 62
36457788 2023
5
Spinal Infections. 62
36404042 2023
6
Autoimmune conditions and pancreatic cancer risk in older American adults. 62
36059225 2023
7
Xinfeng capsule inhibits inflammation and oxidative stress in rheumatoid arthritis by up-regulating LINC00638 and activating Nrf2/HO-1 pathway. 62
36272490 2023
8
Work-related Issues, Physical and Psychological Burden in Canadian Axial Spondyloarthritis Patients. Results From the International Map of Axial Spondyloarthritis. 62
36455954 2022
9
Pulmonary sarcoidosis with a cavitary lesion in the lung caused by a TNF-α inhibitor: A case report. 62
36415783 2022
10
Pregnant women with immune mediated inflammatory diseases who discontinue biologics have higher rates of disease flare. 62
35249153 2022
11
Long-term clinical results from 10 years follow-up after radiosynoviorthesis: a prospective observational study. 62
36106912 2022
12
JAK: Not Just Another Kinase. 62
36252553 2022
13
Systematic Literature Review of the Use of Productivity Losses/Gains in Cost-Effectiveness Analyses of Immune-Mediated Disorders. 62
36205907 2022
14
Risk of Severe COVID-19 Outcomes Among Patients with Immune-Mediated Inflammatory Diseases or Malignancies: A Retrospective Analysis of Real-World Data in the United States. 62
36153800 2022
15
MicroRNAs-mediated regulation pathways in rheumatic diseases. 62
36469219 2022
16
Ochronotic arthropathy in the context of spondyloarthritis differential diagnosis: a case-based review. 62
36053307 2022
17
Novel Biomarker of Collagen Degradation Can Identify Patients Affected With Both Axial Spondyloarthritis and Crohn Disease. 62
35705233 2022
18
Interleukin (IL)-33 immunobiology in asthma and airway inflammatory diseases. 62
34928757 2022
19
Review on skeletal disorders caused by Staphylococcus spp. in poultry. 62
35076352 2022
20
One-third of European axial spondyloarthritis patients reach pain"remission" with routine care TNF-inhibitor treatment. 62
36455943 2022
21
Effect of cervical stabilization exercises on cervical position error in patients with axial spondyloarthritis: a randomized controlled pilot study. 62
36459172 2022
22
Long-Term Adherence to Etanercept in Treatment Effectiveness of Patients with Spondyloarthritis: 7-Year Data from the Iraq National Registry. 62
36178583 2022
23
Clinical features and outcomes of spine surgery in patients with ankylosing spondylitis. 62
36469006 2022
24
Isolated axial disease in psoriatic arthritis and ankylosing spondylitis with psoriasis. 62
35973805 2022
25
T cell Repertoire Profiling and the Mechanism by which HLA-B27 Causes Ankylosing Spondylitis. 62
36197645 2022
26
Association between disability scores and opioid use in patients with psoriatic arthritis and ankylosing spondylitis. 62
36469081 2022
27
Response to 'Correspondence on "Tumour necrosis factor inhibitors slow radiographic progression in patients with ankylosing spondylitis: 18-year real-world evidence" by Zhang et al. 62
33004327 2022
28
Correspondence on 'Tumour necrosis factor inhibitors slow radiographic progression in patients with ankylosing spondylitis: 18-year real-world evidence'. 62
33004326 2022
29
The effect of anti-TNF on renal function in patients with ankylosing spondylitis: a prospective cohort study. 62
35962246 2022
30
Surgery for degenerative cervical myelopathy in patients with rheumatoid arthritis and ankylosing spondylitis: a nationwide registry-based study with patient-reported outcomes. 62
36241742 2022
31
Efficacy and Safety of Intravenous Golimumab in Patients With Ankylosing Spondylitis and Complete Spinal Ankylosis: Results Through Week 52 of the GO-ALIVE Study. 62
35649533 2022
32
Internal fixation for fragility fracture of pelvis in a patient with ankylosing spondylitis. 62
36276501 2022
33
Risk of Hematologic Malignancies in Elderly Patients With Ankylosing Spondylitis: A Cohort Study and Systematic Review. 62
36470752 2022
34
Heavy Calcification of Left Atrium and Calcific Mass on Mitral Valve: An Unusual Presentation of Ankylosing Spondylitis. 62
35976239 2022
35
Diagnostic serum biomarkers associated with ankylosing spondylitis. 62
36459277 2022
36
The genetic backbone of ankylosing spondylitis: how knowledge of genetic susceptibility informs our understanding and management of disease. 62
35939079 2022
37
Relationship Between Inflammation and Radiographic Progression in Patients With Ankylosing Spondylitis Attaining a BASDAI of Less Than 4 During Tumor Necrosis Factor Inhibitor Treatment. 62
35840153 2022
38
Circ_0018168 inhibits the proliferation and osteogenic differentiation of fibroblasts in ankylosing spondylitis via regulating miR-330-3p/DKK1 axis. 62
35891711 2022
39
Gold threads around the sacroiliac joints: traces of attempts to relieve pain in a case of advanced ankylosing spondylitis. 62
35882567 2022
40
JAK-STAT signaling pathway-related gene single nucleotide polymorphisms and susceptibility to ankylosing spondylitis in eastern Chinese Han population. 62
36355252 2022
41
Increased oxidative and chromosomal DNA damage in patients with ankylosing spondylitis: its role in pathogenesis. 62
36441439 2022
42
Cervical Spine Fracture Prediction by Simple Plain X-Ray in Ankylosing Spondylitis Patients after Low-Energy Trauma. 62
36178011 2022
43
Serum PCSK9 is positively correlated with disease activity and Th17 cells, while its short-term decline during treatment reflects desirable outcomes in ankylosing spondylitis patients. 62
36344709 2022
44
Evaluation of middle ear and hearing status of ankylosing spondylitis patients with wideband tympanometry and pure tone audiometry tests. 62
36385656 2022
45
Features of Peripheral Blood Th-Cell Subset Composition and Serum Cytokine Level in Patients with Activity-Driven Ankylosing Spondylitis. 62
36355542 2022
46
Ankylosing spondylitis disease activity and serum vitamin D levels: A systematic review and meta-analysis. 62
36401455 2022
47
Clinical Images: A snapshot from the past: untreated ankylosing spondylitis in the biologic era. 62
36448254 2022
48
MicroRNA-155 acts as a potential prognostic and diagnostic factor in patients with ankylosing spondylitis by modulating SOCS3. 62
36350418 2022
49
The value of the sacroiliac joint area as a new morphological parameter of ankylosing spondylitis. 62
36397357 2022
50
Outcomes of spinal cord injury following cervical fracture in ankylosing spondylitis and diffuse idiopathic skeletal hyperostosis (DISH): A prospective cohort study. 62
36333086 2022

Variations for Spondylitis

Expression for Spondylitis

Search GEO for disease gene expression data for Spondylitis.

Pathways for Spondylitis

Pathways related to Spondylitis according to GeneCards Suite gene sharing:

(show all 42)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.6 TNF LTA IL6 IL23R IL23A IL1B
2
Show member pathways
13.38 TNF LTA IL6 IL23R IL23A IL1B
3
Show member pathways
13.27 TNF LTA IL6 IL23R IL23A IL1B
4
Show member pathways
13.25 TNF SAA1 NOD2 LTA IL6 IL23R
5
Show member pathways
13.13 TNF TAP2 TAP1 SAA1 NOD2 MICA
6
Show member pathways
12.6 HLA-B HLA-C IL17A IL1B IL23R IL6
7
Show member pathways
12.57 IL17A IL1B IL23A IL23R IL6 TNF
8 12.55 IL17A IL1B TAP1 TAP2 TNF
9
Show member pathways
12.48 TNF NOD2 IL6 IL1B
10
Show member pathways
12.3 HLA-B HLA-C TAP1 TAP2
11
Show member pathways
12.13 TNF LTA IL23R IL23A IL17A
12 12.09 TNF LTA IL6 IL1B
13
Show member pathways
11.89 IL6 IL23R IL23A IL1B IL17A
14
Show member pathways
11.88 IL17A IL1B IL23R IL6 LTA TNF
15
Show member pathways
11.86 IL6 IL23R IL23A IL17A
16 11.83 TNF SAA1 IL6 IL23R IL23A IL1B
17 11.81 TNF MICA IL1B IL17A HLA-C HLA-B
18
Show member pathways
11.76 TNF LTA IL1B
19 11.75 TNF IL6 IL23A IL1B
20 11.73 TNF IL6 IL1B
21 11.71 IL6 IL23R IL23A IL1B IL17A
22 11.7 TNF IL6 CRP
23 11.66 TNF LTA IL6 IL1B
24
Show member pathways
11.64 TNF IL6 IL1B
25 11.64 TNF IL6 IL1B
26
Show member pathways
11.63 TNF NOD2 IL6 IL23R IL23A
27 11.6 CCR6 IL17A IL1B IL23A IL23R LTA
28 11.54 TNF NOD2 IL6
29 11.5 TNF IL6 IL1B
30 11.48 TNF IL6 IL1B
31 11.38 TAP1 IL1B HLA-B
32 11.34 TNF IL6 IL1B
33 11.27 TNF IL6 IL1B IL17A
34 11.26 TNF IL6 IL1B
35 11.24 IL1B IL6 TNF
36 11.24 TNF IL6 IL23A IL17A
37 11.22 TNF IL6 IL23A IL1B IL17A
38 11.04 TNF IL6 CRP
39 11 TNF LTA IL6 IL23A IL1B IL17A
40 10.9 TAP2 TAP1 HLA-C HLA-B ERAP2 ERAP1
41 10.76 IL6 IL1B
42
Show member pathways
10.35 TNF IL6

GO Terms for Spondylitis

Cellular components related to Spondylitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 TAP complex GO:0042825 9.26 TAP2 TAP1
2 phagocytic vesicle membrane GO:0030670 9.23 TAP2 TAP1 HLA-C HLA-B

Biological processes related to Spondylitis according to GeneCards Suite gene sharing:

(show all 45)
# Name GO ID Score Top Affiliating Genes
1 innate immune response GO:0045087 10.47 NOD2 IL23R IL23A IL17A HLA-C HLA-B
2 inflammatory response GO:0006954 10.42 TNF IL6 IL23R IL23A IL1B IL17A
3 adaptive immune response GO:0002250 10.41 TAP2 TAP1 IL17A HLA-C HLA-B ERAP2
4 positive regulation of tumor necrosis factor production GO:0032760 10.26 NOD2 IL6 IL23A IL17A
5 defense response to Gram-negative bacterium GO:0050829 10.25 IL6 IL23R IL23A IL17A
6 positive regulation of interleukin-6 production GO:0032755 10.24 IL17A IL1B IL6 NOD2 TNF
7 positive regulation of NIK/NF-kappaB signaling GO:1901224 10.23 TNF NOD2 IL23A IL1B
8 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 10.23 TNF IL6 IL23R IL23A
9 defense response GO:0006952 10.22 HLA-B NOD2 TAP1 TNF
10 positive regulation of interleukin-8 production GO:0032757 10.22 IL1B IL6 NOD2 TNF
11 positive regulation of interleukin-1 beta production GO:0032731 10.22 TNF NOD2 IL6 IL17A
12 positive regulation of T cell proliferation GO:0042102 10.21 IL6 IL23R IL23A IL1B
13 response to lipopolysaccharide GO:0032496 10.21 IL1B IL23R LTA NOD2 TNF
14 humoral immune response GO:0006959 10.19 CCR6 IL6 LTA TNF
15 positive regulation of type II interferon production GO:0032729 10.19 TNF LTA IL23R IL23A IL1B
16 regulation of insulin secretion GO:0050796 10.17 TNF IL6 IL1B
17 positive regulation of interleukin-10 production GO:0032733 10.16 IL23A IL6 NOD2
18 positive regulation of interleukin-12 production GO:0032735 10.16 NOD2 IL23R IL23A IL17A
19 acute-phase response GO:0006953 10.15 SAA1 IL6 CRP
20 negative regulation of neurogenesis GO:0050768 10.13 IL1B IL6 TNF
21 positive regulation of chemokine production GO:0032722 10.09 TNF IL6 IL1B
22 positive regulation of cytokine production involved in inflammatory response GO:1900017 10.08 TNF NOD2 IL6 IL17A
23 positive regulation of granulocyte macrophage colony-stimulating factor production GO:0032725 10.06 IL23R IL23A IL1B
24 positive regulation of interleukin-17 production GO:0032740 10.06 IL23A IL23R IL6 NOD2
25 positive regulation of neuroinflammatory response GO:0150078 10.04 IL1B IL6 TNF
26 positive regulation of T cell mediated cytotoxicity GO:0001916 10.03 TAP2 IL23R IL23A HLA-B
27 negative regulation of lipid storage GO:0010888 10.02 TNF IL6 CRP
28 positive regulation of osteoclast differentiation GO:0045672 10.01 TNF IL23R IL23A IL17A
29 vascular endothelial growth factor production GO:0010573 10 TNF IL6 IL1B
30 regulation of tyrosine phosphorylation of STAT protein GO:0042509 9.99 IL23R IL23A
31 antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independent GO:0002486 9.99 HLA-C HLA-B
32 positive regulation of humoral immune response mediated by circulating immunoglobulin GO:0002925 9.99 TNF NOD2 LTA
33 positive regulation of NK T cell activation GO:0051135 9.98 IL23R IL23A
34 positive regulation of fever generation GO:0031622 9.98 TNF IL1B
35 positive regulation of T-helper 17 cell lineage commitment GO:2000330 9.97 IL23R IL23A
36 sequestering of triglyceride GO:0030730 9.97 TNF IL1B
37 positive regulation of glial cell proliferation GO:0060252 9.97 TNF LTA IL6 IL1B
38 defense response to Gram-positive bacterium GO:0050830 9.97 TNF NOD2 LTA IL6 IL1B IL17A
39 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.96 TNF IL1B
40 cytosol to endoplasmic reticulum transport GO:0046967 9.94 TAP2 TAP1
41 positive regulation of chronic inflammatory response to antigenic stimulus GO:0002876 9.94 TNF LTA
42 antigen processing and presentation of endogenous peptide antigen via MHC class I GO:0019885 9.86 ERAP1 ERAP2 TAP1 TAP2
43 immune response GO:0006955 9.83 CCR6 HLA-B HLA-C IL17A IL1B IL23A
44 antigen processing and presentation of peptide antigen via MHC class I GO:0002474 9.8 HLA-C HLA-B ERAP2 ERAP1
45 immune system process GO:0002376 9.32 TAP2 TAP1 NOD2 IL23R IL23A IL17A

Molecular functions related to Spondylitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 TAP1 binding GO:0046978 9.73 TAP2 TAP1
2 cytokine activity GO:0005125 9.73 TNF LTA IL6 IL23A IL1B IL17A
3 MHC class Ib protein binding GO:0023029 9.71 TAP2 TAP1
4 ABC-type peptide antigen transporter activity GO:0015433 9.67 TAP2 TAP1
5 peptide transmembrane transporter activity GO:1904680 9.62 TAP2 TAP1
6 ABC-type peptide transporter activity GO:0015440 9.56 TAP2 TAP1
7 TAP binding GO:0046977 9.46 HLA-B HLA-C
8 peptide antigen binding GO:0042605 9.23 TAP2 TAP1 HLA-C HLA-B

Sources for Spondylitis

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....